Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

(New MS Research) Artielle ImmunoTherapeutics Announces Positive Results of Phase 1 Multiple Sclerosis Trial

Posted Nov 17 2009 10:20pm
Results Presented at 13th Congress of the European Federation of Neurological Societies in Florence, Italy

PORTLAND, Ore., Sept. 14 /PRNewswire/ -- Artielle ImmunoTherapeutics, a clinical stage biopharmaceutical company announced today the presentation of "Results of a Phase 1 safety study of RTL1000, a recombinant T-Cell receptor ligand specific for an immunodominant MOG peptide, in multiple sclerosis." The results were presented yesterday by one of Artielle's founding scientists, Arthur Vandenbark, Ph.D., at the Congress of the European Federation of Neurological Societies in Florence, Italy. The presentation showed that this Phase 1 Study met its primary objective, which was to evaluate the safety profile and determine the maximum tolerated dose (MTD) of a single IV dose of RTL1000. Secondary objectives of the study were also met; these were to determine the pharmacokinetic profile of RTL1000 and assess immunologic parameters in a subset of Multiple Sclerosis (MS) patients. This was a first-in-human, double-blind, placebo controlled trial that enrolled 34 subjects with relapsing remitting and secondary progressive MS at six centers in the United States. All subjects were followed for clinical and MRI changes, pharmacokinetics and cytokine levels in plasma and blood mononuclear cells.

Click here to continue.

and click here (to register) if not yet receiving the "Stu's Views and MS News", weekly MS related e-
newsletter

============================================
Post a comment
Write a comment: